Payment overview · 2025
General Payments
$538.10
17 reported records · 6 companies
Healthcare provider profile · identity verified
Evodio Hector Estrada
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · OKLAHOMA CITY, OK · NPI 1659902385
Verified facts
What the public records show
CMS Open Payments records show Evodio Hector Estrada received $538.10 in general payments during 2025 across 17 reported records.
Pulmonx Corporation accounted for 45.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $246.49 | 45.8% | 3 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $103.49 | 19.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $82.93 | 15.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.18 | 9.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.33 | 7.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.68 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $538.10 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $246.49 | 3 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $246.49 | 3 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $246.49 | 3 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $246.49 | 3 | 2025 |
Source payment records
|
|||||
| Hillrom - Monarch Airway Clearance System Normalized: hillrom monarch airway clearance system |
Device | Baxter Healthcare | $103.49 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.93 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.18 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.80 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $39.33 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $37.68 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 117 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
117 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
117 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 632 | 244 |
| Lisinopril | Lisinopril | 424 | 140 |
| Metformin Hcl | Metformin Hcl | 318 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 314 | 133 |
| Gabapentin | Gabapentin | 241 | 90 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 232 | 101 |
| Losartan Potassium | Losartan Potassium | 179 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 171 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 162 | 57 |
| Carvedilol | Carvedilol | 129 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 48 |
| Omeprazole | Omeprazole | 124 | 49 |
| Jardiance | Empagliflozin | 117 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 41 |
| Potassium Chloride | Potassium Chloride | 111 | 45 |
| Furosemide | Furosemide | 109 | 49 |
| Alendronate Sodium | Alendronate Sodium | 106 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 40 |
| Trazodone Hcl | Trazodone Hcl | 106 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 36 |
| Sertraline Hcl | Sertraline Hcl | 88 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 45 |
| Glipizide | Glipizide | 74 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 24 |
| Naproxen | Naproxen | 73 | 29 |
| Ibuprofen | Ibuprofen | 71 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 23 |
| Simvastatin | Simvastatin | 68 | 25 |
| Eliquis | Apixaban | 64 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 20 |
| Ozempic | Semaglutide | 61 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 28 |
| Meloxicam | Meloxicam | 57 | 22 |
| Celecoxib | Celecoxib | 56 | 20 |
| Montelukast Sodium | Montelukast Sodium | 53 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | suppressed |
| Famotidine | Famotidine | 45 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 24 |
| Meclizine Hcl | Meclizine Hcl | 43 | 24 |
| Ondansetron Odt | Ondansetron | 41 | 23 |
| Baclofen | Baclofen | 39 | suppressed |
| Mirtazapine | Mirtazapine | 38 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 12 |
| Buspirone Hcl | Buspirone Hcl | 36 | 11 |
| Donepezil Hcl | Donepezil Hcl | 35 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 15 |
| Alprazolam | Alprazolam | 31 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 23 |
| Tradjenta | Linagliptin | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | 11 |
| Novolog Flexpen | Insulin Aspart | 27 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Xifaxan | Rifaximin | 23 | suppressed |
| Ibu | Ibuprofen | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 20 |
| Prednisone | Prednisone | 22 | 22 |
| Spironolactone | Spironolactone | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 20 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | 11 |
| Torsemide | Torsemide | 19 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 14 |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $538.10 · 17 records | Pulmonx Corporation | AIRSUPRA, CHARTIS CATHETER, Hillrom - Monarch Airway Clearance System, JARDIANCE, MOUNJARO, PULMONX CHARTIS TABLET CONSOLE, The Cologuard Plus Collection Kit, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error